Recap: Ultragenyx Pharmaceutical Q3 Earnings

Shares of Ultragenyx Pharmaceutical RARE were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 42.35% over the past year to ($1.13), which beat the estimate of ($1.27).

Revenue of $81,470,000 up by 215.78% year over year, which beat the estimate of $53,890,000.

Looking Ahead

Ultragenyx Pharmaceutical hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Oct 27, 2020

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/yvtmu8mm

Recent Stock Performance

52-week high: $99.25

52-week low: $31.99

Price action over last quarter: Up 24.67%

Company Description

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.